GluGene Therapeutics presents new possibilities for treating intractable diseases through innovative technologies that overcome the structural limitations of AAV‑based gene therapy.

Built upon our proprietary vector engineering and process development capabilities, GluGene Therapeutics has established an end‑to‑end integrated platform for gene therapy development, seamlessly connecting the entire continuum from scientific discovery to clinical application.

By fundamentally enhancing the delivery efficiency, precision, and functionality of AAV vectors and overcoming the limitations of conventional approaches, we aim to deliver the core value of gene therapy to a broader patient population. Through strategic collaborations with global pharmaceutical partners, we continue to expand the therapeutic potential of AAV‑based gene therapy and advance toward becoming a global leader in the field.